The researchers note that although the FDA recommends the use of non-CYP3A4–metabolised statins as a safer alternative when taken concurrently with CYP3A4 inhibitors, their data indicate that unintended adverse events may still occur, possibly because of additional mechanisms of drug interactions independent of the CYP3A4 pathway. They suggest that in order to prevent toxicity, the use of azithromycin or another antibiotic that does not interact with statins should considered.